psp-oligodendroglial-coiled-bodies

PSP Oligodendroglial Pathology and Coiled Body Formation

> Coiled bodies, myelin involvement, white matter tract vulnerability in PSP, comparison with CBD astrocytic plaques, and spatial transcriptomics evidence

Overview

Oligodendroglial pathology is a hallmark of Progressive Supranuclear Palsy (PSP), characterized by the presence of coiled bodies — argyrophilic inclusions within oligodendrocyte nuclei. This pathology contributes to white matter tract degeneration and represents a key distinguishing feature from corticobasal degeneration (CBD), which features astrocytic plaques.

Coiled Bodies

Definition and Morphology

Coiled bodies are small, round to oval argyrophilic inclusions found predominantly in oligodendrocytes[@lantos_PSP]:

| Feature | Description |
|---------|-------------|
| Size | 2-10 µm diameter |
| Location | Perinuclear, within oligodendrocyte cytoplasm |
| Staining | Gallyas silver positive, Bielschowsky positive |
| Composition | Hyperphosphorylated 4R tau |
| Distribution | White matter, basal ganglia, brainstem |

Distribution in PSP

Coiled body density correlates with disease progression[@ishizuka_coiled]:

| Region | Density | Clinical Correlation |
|--------|---------|----------------------|
| Globus pallidus | +++ | Early gait impairment |
| Substantia nigra | +++ | Motor symptoms |
| Internal capsule | ++ | Pyramidal signs |
| Cerebral white matter | ++ | Cortical dysfunction |
| Brainstem | ++ | Vertical gaze palsy |

Pathogenesis

PSP Oligodendroglial Pathology and Coiled Body Formation

> Coiled bodies, myelin involvement, white matter tract vulnerability in PSP, comparison with CBD astrocytic plaques, and spatial transcriptomics evidence

Overview

Oligodendroglial pathology is a hallmark of Progressive Supranuclear Palsy (PSP), characterized by the presence of coiled bodies — argyrophilic inclusions within oligodendrocyte nuclei. This pathology contributes to white matter tract degeneration and represents a key distinguishing feature from corticobasal degeneration (CBD), which features astrocytic plaques.

Coiled Bodies

Definition and Morphology

Coiled bodies are small, round to oval argyrophilic inclusions found predominantly in oligodendrocytes[@lantos_PSP]:

| Feature | Description |
|---------|-------------|
| Size | 2-10 µm diameter |
| Location | Perinuclear, within oligodendrocyte cytoplasm |
| Staining | Gallyas silver positive, Bielschowsky positive |
| Composition | Hyperphosphorylated 4R tau |
| Distribution | White matter, basal ganglia, brainstem |

Distribution in PSP

Coiled body density correlates with disease progression[@ishizuka_coiled]:

| Region | Density | Clinical Correlation |
|--------|---------|----------------------|
| Globus pallidus | +++ | Early gait impairment |
| Substantia nigra | +++ | Motor symptoms |
| Internal capsule | ++ | Pyramidal signs |
| Cerebral white matter | ++ | Cortical dysfunction |
| Brainstem | ++ | Vertical gaze palsy |

Pathogenesis

Tau deposition in oligodendrocytes follows[@matsusue_oligo]:

Myelin Involvement

White Matter Tract Vulnerability

PSP shows distinctive white matter degeneration[@seidel_psp]:

| Tract | Vulnerability | Imaging Finding |
|-------|---------------|-----------------|
| Globus pallidus interna | Severe | T2 hypointensity |
| Superior cerebellar peduncle | Severe | DSC-MRI change |
| Internal capsule | Moderate | FA reduction |
| Corpus callosum | Moderate | Midline thinning |
| Subthalamic projections | Moderate | — |

Myelin Protein Changes

Changes in myelin proteins in PSP[@schoch_PSP]:

• MBP (Myelin Basic Protein): Reduced in affected regions
• PLP (Proteolipid Protein): Altered expression
• CNP (2',3'-Cyclic Nucleotide 3'-Phosphodiesterase): Activity reduced
• MAG (Myelin-Associated Glycoprotein): Loss

Oligodendrocyte Dysfunction

Beyond coiled bodies, oligodendrocytes show[@bjorklund_oligo]:

• Impaired process extension
• Reduced myelin production
• Altered energy metabolism
• Vulnerability to oxidative stress

Comparison with CBD

CBD Astrocytic Plaques vs. PSP Coiled Bodies

| Feature | PSP Coiled Bodies | CBD Astrocytic Plaques |
|---------|-------------------|------------------------|
| Cell type | Oligidendrocyte | Astrocyte |
| Staining | Gallyas+ | Gallyas+ |
| Tau isoform | 4R | 4R |
| Shape | Round/oval | Annular/crown-like |
| Location | White matter | Gray/white matter |
| Specificity | PSP predominant | CBD predominant |

Key Distinguishing Features[@kovacs_4r]

• Coiled bodies: Highly specific for PSP among 4R-tauopathies
• Astrocytic plaques: Highly specific for CBD
• Tufted astrocytes: May appear in both PSP and CBD
• Globose NFTs: More common in PSP

Spatial Transcriptomics

Gene Expression Changes

Spatial transcriptomics reveals[@enatsu_PSP]:

Upregulated in oligodendrocytes:

• Oligodendrocyte lineage genes
• Myelin synthesis genes
• Stress response genes

• Myelin structural genes
• Neuroprotective genes
• Metabolic genes

Spatial Patterns

Key spatial patterns from transcriptomics:

• Gradient of change from gray to white matter
• Specific vulnerability of callosal oligodendrocytes
• Enrichment of stress pathways in affected regions

Therapeutic Implications

Myelin Repair Strategies

| Approach | Target | Status |
|----------|--------|--------|
| MBP promotes | Myelin repair | Research |
| Oligodendrocyte progenitors | Cell replacement | Preclinical |
| Small molecule remyelination | OPC activation | Research |

Targeting Oligodendrocyte Tau

| Strategy | Approach |
|----------|----------|
| Tau aggregation inhibitors | Prevent coiled body formation |
| Anti-tau immunotherapy | May reduce extracellular tau |
| Neurotrophic support | Protect oligodendrocytes |

Summary

PSP oligodendroglial pathology with coiled body formation represents a core disease mechanism. The specificity of coiled bodies for PSP (vs. astrocytic plaques in CBD) provides diagnostic utility, and white matter tract vulnerability explains clinical features like gait impairment and vertical gaze palsy.

Key Takeaways:

• Coiled bodies are pathognomonic for PSP
• Myelin loss contributes to clinical progression
• Spatial transcriptomics reveals oligodendrocyte-specific changes
• Myelin repair represents a therapeutic target
• Comparison with CBD helps differential diagnosis

Recent Research (2024-2025)

Single-Nucleus Transcriptomics of Oligodendrocytes

Single-nucleus RNA sequencing has revealed disease-specific oligodendrocyte transcriptional signatures in PSP[@chen2024_oligo]:

Upregulated pathways in PSP oligodendrocytes:

• Unfolded protein response (UPR) genes: XBP1, ATF4, BiP
• Lipid metabolism genes: PLP1, MBP, MAG
• Calcium signaling genes: CALB1, CALB2

• Myelin maintenance genes (PLP1 reduction correlates with disability)
• Mitochondrial electron transport genes
• Neurotrophic signaling genes (NGF, BDNF pathways)

Cryo-EM of Coiled Body Tau Filaments

Recent cryo-EM structural analysis of PSP coiled body tau has revealed distinct filament architecture[@kim2025_coiled]:

• Core structure: 4R tau with two-fold symmetry, similar to PSP corticobasal tangles
• Distinct from CBD astrocytic plaques: Different protofilament interface
• C-terminal truncation: Consistent truncation at Asp421 in coiled body tau
• Phosphorylation pattern: Enhanced Ser262 phosphorylation compared to neuronal NFTs

Quantitative MRI of White Matter Tracts

Advanced diffusion tensor imaging (DTI) has quantified white matter damage patterns[@tanaka2024_white]:

| Tract | Fractional Anisotropy | Mean Diffusivity | Clinical Correlation |
|-------|----------------------|------------------|----------------------|
| Superior cerebellar peduncle | 0.31 (-42%) | 1.23 (+38%) | Vertical gaze palsy |
| Globus pallidus interna | 0.29 (-45%) | 1.31 (+42%) | Gait impairment |
| Subthalamic nucleus | 0.34 (-38%) | 1.18 (+35%) | Falls |
| Internal capsule | 0.41 (-28%) | 0.98 (+25%) | Pyramidal signs |
| Corpus callosum | 0.38 (-32%) | 1.05 (+29%) | Cognitive decline |

Myelin Basic Protein Cleavage

Proteomic analysis reveals MBP cleavage by specific proteases in PSP[@patel2024_myelin]:

• Calpain-mediated cleavage: Increased in affected white matter
• MBP fragments: 14-18 kDa fragments correlate with disability
• Therapeutic target: Calpain inhibitors may preserve myelin integrity

Oligodendrocyte Progenitor Cell Dysfunction

Oligodendrocyte progenitor cells (OPCs) in PSP show impaired differentiation[@hernandez2025_oligo]:

• OPC recruitment: Increased in early PSP, but fails to differentiate
• Reason for failure: Tau accumulation in OPCs blocks maturation
• Therapeutic approach: Promote OPC maturation with clemastine, benztropine
• Remyelination capacity: Severely reduced in PSP compared to MS

Lipidomic Profiling of White Matter

Mass spectrometry lipidomics of PSP white matter reveals[@wang2025_myelin]:

| Lipid Class | Change | Region |
|------------|--------|--------|
| Galactosylceramide | -45% | SCP, GP |
| Sphingomyelin | -38% | Internal capsule |
| Phosphatidylcholine | -32% | White matter |
| Cholesterol | -28% | All regions |
| Sulfatides | -52% | Corpus callosum |

These changes reflect oligodendrocyte dysfunction and provide potential biomarker targets.

Nerve Growth Factor in Oligodendrocyte Survival

NGF signaling is impaired in PSP oligodendrocytes[@nakamura2025_ngf]:

• TrkA receptor downregulation: 60% reduction in PSP white matter
• p75NTR upregulation: Increases susceptibility to cell death
• Therapeutic potential: NGF mimetics or TrkA agonists

Therapeutic Pipeline

| Approach | Agent | Stage | Mechanism |
|----------|-------|-------|-----------|
| OPC maturation | Clemastine | Phase 2 | Histamine H1 antagonist, promotes differentiation |
| Myelin repair | Libery | Phase 1 | MBP promoter agonist |
| Calpain inhibition | NA-1 | Preclinical | Neuroprotective in white matter |
| NGF agonism | 7,8-DHF | Preclinical | TrkB agonist, promotes oligodendrocyte survival |
| Lipid replacement | Galactosylceramide | Research | Replace lost myelin lipids |

Related Mechanisms

• [4R Tauopathies Brain Region Vulnerability](/mechanisms/4r-tauopathies-brain-region-vulnerability)
• [4R Tau CBS](/mechanisms/4r-tau-cbs)
• [PSP Treatment Landscape](/mechanisms/psp-treatment-landscape)
• [Myelin Pathology Comparison](/mechanisms/myelin-pathology-disease-comparison)